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Objectives: To determine the antibiotic susceptibility of respiratory isolates of Streptococcus pneumoniae and
Haemophilus influenzae collected in 2011–13 from Ukraine.
Methods: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST
and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Results:A total of 134 isolates of S. pneumoniae and 67 ofH. influenzaewere collected from eight sites in Ukraine.
Overall, 87.3% of S. pneumoniae were penicillin susceptible by CLSI oral breakpoints and 99.3% by CLSI iv
breakpoints. Susceptibility to amoxicillin/clavulanic acid (amoxicillin), ceftriaxone and levofloxacin was 100%
by CLSI and PK/PD breakpoints. Cephalosporin and macrolide susceptibility was≥95.5% and 88.1%, respectively
using CLSI breakpoints. Trimethoprim/sulfamethoxazole was essentially inactive against pneumococci. Of the 67
H. influenzae tested, 4.5% were b-lactamase positive and all H. influenzae were fully susceptible to amoxicillin/
clavulanic acid, ceftriaxone, ciprofloxacin, cefixime and levofloxacin (all breakpoints). Cefuroxime susceptibility
was 100% by CLSI but 73.1% by EUCAST and PK/PD breakpoints. A discrepancy was found in macrolide suscep-
tibility between CLSI (100% susceptible), EUCAST (22%–43% susceptible) and PK/PD (0%–22% susceptible)
breakpoints. Trimethoprim/sulfamethoxazole was poorly active (59.7% susceptible).
Conclusions: Generally, antibiotic resistance was low in respiratory pathogens from Ukraine. However, only
amoxicillin/clavulanic acid (amoxicillin), ceftriaxone and levofloxacin were fully active against both species.
Trimethoprim/sulfamethoxazole was the least active, particularly against S. pneumoniae. Some susceptibility
differences were apparent between CLSI, EUCAST and PK/PD breakpoints, especially with macrolides against
H. influenzae. These data suggest that further efforts are required to harmonize these international breakpoints.
Future studies are warranted to monitor continued low resistance levels in Ukraine compared with other parts of
Eastern Europe.
Introduction
Community-acquired pneumonia (CAP) and other lower respira-
tory tract infections (LRTIs) are the second most frequent cause
of all-age premature deaths worldwide.1 CAP and other LRTIs
are also a major cause of morbidity among children aged
,5 years, causing 12 million hospital admissions per annum2
and 1.6 million deaths in young children3 worldwide. CAP also
imposes a substantial disease burden on older children4 and
adults.5,6 Improving the therapeutic management of pneumonia
is one of the top priorities, as defined by international experts, to
decrease the CAP burden and improve health worldwide.7
Clinical diagnosis of CAP can be problematic, especially in
patients with underlying pulmonary conditions.8 This diagnosis
may be influenced by available microbiological testing methods
or impeded by antibiotic intake prior to testing.9 Streptococcus
pneumoniae and Haemophilus influenzae are the main bacterial
pathogens associated with community-acquired respiratory
tract infections.10 Antimicrobial resistance in these pathogens
is common and resistance surveillance plays an important role
in the reporting and management of LRTI. One such study is
the ongoing Survey of Antibiotic Resistance (SOAR), which is an
antimicrobial resistance surveillance study of key respiratory
pathogens conducted in the Middle East, Africa, Latin America,
Asia-Pacific and Commonwealth of Independent States countries
and has been running since 2002. Here we report recent data from
SOAR for major respiratory tract pathogens collected from hos-
pital sites in the Ukraine.
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Materials and methods
Collaborating centres
The following eight centres took part in the study: National Institute of
Tuberculosis and Pulmonology, Kiev, Ukraine; Regional Pediatric Clinic,
Kiev, Ukraine; Dnepropetrovsk State Medical Academy, Dnepropetrovsk,
Ukraine; Vinnitsa State Pirogov Memorial Medical University, Vinnitsa,
Ukraine; Regional Pediatric Clinic, Lviv, Ukraine; Regional Hospital,
Ivano-Frankivsk Ukraine; Regional Hospital, Simferopol, Ukraine; and
Regional Children’s Hospital, Zaporozhye, Ukraine.
Clinical isolates
Isolates were collected (from community-acquired infections/outpati-
ents/university hospitals) during 2011–13 from a variety of sources,
including bronchoalveolar lavage, middle ear effusion, pleural aspirate,
sinus aspirate, sputum and tracheal aspirate. Organisms were identified
using conventional methods (optochin susceptibility/bile solubility
for S. pneumoniae and X and V factor requirement for H. influenzae).
b-Lactamase production was determined for each H. influenzae isolate
by a chromogenic cephalosporin (nitrocefin) disc method. Duplicate iso-
lates from the same patient were not accepted.
Susceptibility testing
Isolates were evaluated for antibiotic susceptibility using broth microdilu-
tion methodology recommended by CLSI.11
All isolates were tested for susceptibility to amoxicillin/clavulanic acid
(2:1; data for amoxicillin alone can be inferred from data for S. pneumoniae
isolates), azithromycin, cefixime, ceftriaxone, cefuroxime, ciproflox-
acin, clarithromycin, levofloxacin and trimethoprim/sulfamethoxazole.
S. pneumoniae were additionally tested with penicillin and erythromycin.
H. influenzae were also tested with ampicillin. Quality control strains
S. pneumoniae ATCC 49619, Escherichia coli ATCC 25922, H. influenzae
ATCC 49247, H. influenzae ATCC 49766 and E. coli ATCC 32518 were
included on each day of testing. Results of susceptibility testing were
accepted if the results of the control strains were within published limits.
Susceptibility to the study drugs was calculated based on CLSI break-
points,12 EUCAST breakpoints13 and pharmacokinetic/pharmacodynamic
(PK/PD) breakpoints.14 These breakpoints are shown in Table 1.
Results
S. pneumoniae
A total of 134 S. pneumoniae isolates were collected from eight dif-
ferent centres in Ukraine from 2011 to 2013. Infection origins of the
pneumococci included tracheal aspirates (n¼55; 41.0%), sputum
(n¼44; 32.8%) and bronchoalveolar lavage (n¼20; 14.9%). Less
frequently, isolates were from sinuses (n¼9; 6.7%), middle
ear effusion (n¼4; 3.0%) and pleural aspirates (n¼2; 1.5%). Most
isolates (n¼82; 61.2%) came from adult patients (aged 13–
64 years), 34 (25.4%) were from children (aged ≤12 years) and
16 (11.9%) were from elderly patients (aged ≥65 years). The
remaining two isolates were from patients of unknown age.
Summary MIC and susceptibility data for all 134 S. pneumoniae
isolates are shown in Table 2. MIC distribution data are given in
Table 3.
Overall, 99.3% (133/134) of S. pneumoniae were penicillin
susceptible, 0.7% (1/134) were penicillin intermediate and
none was penicillin resistant by CLSI penicillin iv (non-meningitis)
Table 1. MIC breakpoints (mg/L) used for S. pneumoniae and H. influenzae isolates
S. pneumoniae breakpoints (mg/L) H. influenzae breakpoints (mg/L)
CLSI EUCAST CLSI EUCAST PK/PD MIC
(mg/L)
Antimicrobial S I R S I R S I R S I R (S only)
Amoxicillin/clavulanic acida ≤2 4 ≥8 NA NA NA ≤4 — ≥8 ≤2 — ≥4 ≤2 (≤4)
Ampicillin NT NT NT NT NT NT ≤1 2 ≥4 ≤1 — ≥2 NA
Cefixime NA NA NA NA NA NA ≤1 — — ≤0.12 — ≥0.25 ≤1
Ceftriaxone ≤1 2 ≥4 ≤0.5 1–2 ≥4 ≤2 — — ≤0.12 — ≥0.25 ≤1
Cefuroximeb ≤1 2 ≥4 ≤0.25 0.5 ≥1 ≤4 8 ≥16 ≤0.12 0.25–1 ≥2 ≤1
Azithromycin ≤0.5 1 ≥2 ≤0.25 0.5 ≥1 ≤4 — — ≤0.12 0.25–4 ≥8 ≤0.12
Clarithromycin ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 ≤8 16 ≥32 ≤1 2–32 ≥64 ≤0.25
Erythromycin ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 NA NA NA ≤0.5 1–16 ≥32 ≤0.25
Ciprofloxacin NA NA NA ≤0.12 0.25–2 ≥4 ≤1 — — ≤0.5 — ≥1 ≤1
Levofloxacin ≤2 4 ≥8 ≤2 — ≥4 ≤2 — — ≤1 — ≥2 ≤2
Penicillin (iv non-meningitis) ≤2 4 ≥8 NAc NAc NAc NA NA NA NA NA NA NA
Penicillin (oral) ≤0.06 0.12–1 ≥2 ≤0.06 0.12–2 ≥4 NA NA NA NA NA NA NA
Trimethoprim/sulfamethoxazole ≤0.5 1–2 ≥4 ≤1 2 ≥4 ≤0.5 1–2 ≥4 ≤0.5 — ≥1 ≤0.5
S, susceptible; I, intermediate; R, resistant; NT, not tested; NA, not applicable.
aAmoxicillin/clavulanic acid was tested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component. PK/PD
breakpoints based on high dose (4 g of amoxicillin with 250 mg of clavulanate per day for adults) shown in parentheses,14 which is the same as
CLSI for H. influenzae and one dilution higher for S. pneumoniae.
bBreakpoints used are for cefuroxime axetil.
cEUCAST do not give iv breakpoints but dose-specific susceptible breakpoints are noted for pneumonia: 1.2 g×4 (MIC ≤0.5 mg/L¼susceptible), 1.2 g×6
or 2.4 g×4 (MIC ≤1 mg/L¼susceptible) and 2.4 g×6 (MIC ≤2 mg/L¼susceptible).
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breakpoints. However, based on CLSI penicillin oral breakpoints or
EUCAST breakpoints 87.3% (117/134) were penicillin susceptible,
11.9% (16/134) were penicillin intermediate and 0.7% (1/134)
were penicillin resistant (Table 2). Using EUCAST dose-dependent
iv breakpoints, penicillin susceptibility ranged from 94.8% (low
dose) to 99.3% (high dose).
All isolates of S. pneumoniae were susceptible to amoxicillin/
clavulanic acid (and by inference amoxicillin alone), ceftriaxone
and levofloxacin by CLSI and PK/PD breakpoints. Levofloxacin
was also 100% active using EUCAST breakpoints but ceftriaxone
susceptibility was reduced to 96.3% (129/134) by EUCAST.
Cefuroxime susceptibility was slightly lower than ceftriaxone
susceptibility, at 95.5% (128/134) by CLSI and PK/PD and 89.6%
(120/134) by EUCAST breakpoints. Cefixime breakpoints are
not published by CLSI or EUCAST but susceptibility using PK/PD
breakpoints was 88.8% (119/134). CLSI guidelines indicate that
isolates susceptible to penicillin G (MIC ≤0.06 mg/L) can be
reported as susceptible to amoxicillin, amoxicillin/clavulanate,
ceftriaxone and cefuroxime. Data from this study confirmed
this, as all penicillin-susceptible S. pneumoniae were also suscep-
tible to these b-lactams. However, the reverse was not found. Of
the 17 penicillin-non-susceptible isolates, all were susceptible to
ceftriaxone and amoxicillin/clavulanic acid (amoxicillin) and 11/
17 (64.7%) were susceptible to cefuroxime. A similar ‘expert
rule’ is provided by EUCAST but for penicillins only, i.e. amoxicil-
lin/clavulanate (amoxicillin) in this study. However, unlike CLSI,
individual breakpoints are not provided by EUCAST for amoxicil-
lin/clavulanate to make this comparison.
Susceptibility to all three macrolides tested (azithromycin, cla-
rithromycin and erythromycin) was 88.1% (118/134) by CLSI,
Table 2. MIC and percentage susceptibility data for S. pneumoniae isolates (n¼134)
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial 50% 90% min max %S %I %R %S %S %I %R
Amoxicillin/clavulanic acida 0.015 0.125 0.002 1 100 0 0 100 (100) NA NA NA
Azithromycin 0.06 2 0.008 128 88.1 1.5 10.4 88.1 88.1 0 11.9
Cefixime 0.125 2 0.03 16 NA NA NA 88.8 NA NA NA
Ceftriaxone 0.015 0.25 0.002 1 100 0 0 100 96.3 3.7 0
Cefuroxime 0.015 0.5 0.004 4 95.5 3 1.5 95.5 89.6 0.7 9.7
Ciprofloxacin 1 2 0.25 4 NA NA NA 89.6 0 99.3 0.7
Clarithromycin 0.03 2 0.008 128 88.1 0 11.9 88.1 88.1 0 11.9
Erythromycin 0.03 2 0.008 128 88.1 0 11.9 88.1 88.1 0 11.9
Levofloxacin 1 1 0.5 2 100 — 0 100 100 0 0
Penicillin (iv non-meningitis) 0.015 0.25 0.004 4 99.3 0.7 0 NA NA NA NA
Penicillin (oral) 0.015 0.25 0.004 4 87.3 11.9 0.7 NA 87.3 11.9 0.7
Trimethoprim/sulfamethoxazole 2 32 0.5 64 9.7 41.8 48.5 9.7 38.8 12.7 48.5
50%, concentration required to inhibit 50% of isolates; 90%, concentration required to inhibit 90% of isolates; min, minimum MIC observed;
max, maximum MIC observed; S, susceptible; I, intermediate; R, resistant; NA, not applicable.
aAmoxicillin/clavulanic acid PK/PD susceptibility at high dose shown in parentheses.
Table 3. MIC distribution data for S. pneumoniae isolates (n¼134)
Number of isolates susceptible at MIC (mg/L)
Antimicrobial 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
Amoxicillin/clavulanic acid 2 14 44 48 6 6 1 1 8 4 0 0 0 0 0 0 0
Azithromycin 0 0 2 14 33 64 5 0 0 2 4 0 2 0 0 1 7
Cefixime 0 0 0 1 10 21 63 12 9 3 5 5 4 1 0 0 0
Ceftriaxone 3 4 23 59 20 8 3 3 6 5 0 0 0 0 0 0 0
Cefuroxime 0 2 24 59 18 5 10 2 1 7 4 2 0 0 0 0 0
Ciprofloxacin 0 0 0 0 0 0 0 4 53 63 13 1 0 0 0 0 0
Clarithromycin 0 1 14 32 66 5 0 0 0 2 4 1 1 0 1 0 7
Erythromycin 0 1 9 17 56 35 0 0 0 1 3 1 3 0 0 1 7
Levofloxacin 0 0 0 0 0 0 0 0 20 111 3 0 0 0 0 0 0
Penicillin 0 11 39 52 8 7 2 2 6 6 0 1 0 0 0 0 0
Trimethoprim/sulfamethoxazole 0 0 0 0 0 0 0 0 13 39 17 19 12 18 13 3 0
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EUCASTor PK/PD breakpoints. The least active antimicrobial agent
tested was trimethoprim/sulfamethoxazole, with only 9.7% of
isolates susceptible (13/134) by CLSI or PK/PD breakpoints and
38.8% (52/134) susceptible by EUCAST breakpoints.
Antibiotic susceptibility in S. pneumoniae was also compared
according to age group (adult, 13–64 years old; elderly, ≥65 years
old; children,≤12 years old). Susceptibility by age group according
to CLSI breakpoints is shown in Figure 1. There was no significant
difference for most antibiotics, but trimethoprim/sulfamethoxa-
zole susceptibility was significantly higher in the elderly (37.5%)
than in adults (12.2%, P¼0.012) and also significantly higher
than in paediatric patients (8.8%, P¼0.014).
H. influenzae
A total of 67 H. influenzae isolates were collected from eight
different centres in Ukraine from 2011–13. Infection origins of
the isolates included sputum (n¼56; 83.6%), followed by infre-
quent isolates from sinuses (n¼7; 10.4%) and bronchoalveolar
lavage (n¼4; 6.0%). Most isolates (n¼51; 76.1%) came from
adult patients, 8 (11.9%) were from elderly patients and
7 (10.4%) were from children. The remaining isolate was
from a patient of unknown age. Three isolates (4.5%) were
b-lactamase-positive and none was b-lactamase-negative and
ampicillin-resistant (BLNAR).
Summary MIC and susceptibility data for all 67 H. influenzae
isolates are shown in Table 4. MIC distribution data are given in
Table 5.
Susceptibility was 100% for amoxicillin/clavulanic acid, ceftri-
axone, ciprofloxacin and levofloxacin according to all three break-
point guidelines. Cefuroxime susceptibility was also 100% by CLSI,
but this reduced to 73.1% (49/67) by EUCAST and PK/PD. For the
macrolides a similarly high susceptibility was observed by CLSI:
azithromycin (100%) and clarithromycin (98.5%, 66/67). This
was dramatically reduced by PK/PD breakpoints: azithromycin
(22.4% susceptible, 15/67) and clarithromycin (0% susceptible)
and EUCAST breakpoints: azithromycin (22.4% susceptible, 15/
67) and clarithromycin (43.3% susceptible, 29/67). The least
active agent was trimethoprim/sulfamethoxazole, at 59.7% sus-
ceptible (40/67) by all three breakpoint categories.
Discussion
The increasing prevalence of antimicrobial resistance among the
major community respiratory tract pathogens is a serious global
problem that complicates the management of these infections.
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Figure 1. Percentage susceptibility rates (with 95% CIs) for antimicrobials against S. pneumoniae by age group according to CLSI breakpoints.
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SOAR surveys antimicrobial resistance in key respiratory patho-
gens and is currently conducted throughout the Middle East,
Africa, Latin America, Asia-Pacific and the Commonwealth of
Independent States countries and has been running since 2002.
It was established to provide information on local resistance
patterns among the two most common pulmonary pathogens,
S. pneumoniae and H. influenzae.
S. pneumoniae resistance to antibiotics is a growing problem
and has become an important prognostic factor since it is directly
associated with persistent disease or disease mortality.15,16
In this study, with lower oral dosing, 87.3% of pneumococcal
isolates were found to be susceptible to penicillin using CLSI
oral breakpoints. Therefore, higher iv dosing is required to get
susceptibility close to 100%. However, for many patients with
community-acquired respiratory tract infections an oral therapy
is desired. For this option amoxicillin/clavulanic acid (or amoxicillin
alone, which would be expected to have identical activity) and
levofloxacin remain the only orally available agents with 100%
susceptibility. However, fluoroquinolones are not recommended
for the treatment of paediatric patients. Cefuroxime is also orally
bioavailable but susceptibility was lower, at 95.5% (CLSI or PK/PD)
and 89.6% (EUCAST). The data from this study confirm that iso-
lates of S. pneumoniae susceptible to penicillin G are also suscep-
tible to other penicillins as inferred by CLSI and EUCAST guidelines
and cephalosporins as inferred by CLSI guidelines. Although peni-
cillin resistance was relatively low in Ukraine, the data from this
study showed the reverse was not correct using CLSI breakpoints;
i.e. penicillin-non-susceptible S. pneumoniae were susceptible
to other b-lactams—the most significant being ceftriaxone.
Therefore, either the b-lactam breakpoints are not correct or the
CLSI cross-resistance statement within the b-lactam class is not
correct. This has also been found in other countries with higher
penicillin resistance (SOAR 2011–13 data in other countries, as
seen in other articles in this Supplement) and warrants further
Table 4. MIC and percentage susceptibility data for H. influenzae isolates (n¼67)
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial 50% 90% min max %S %I %R %Sa %S %I %R
Amoxicillin/clavulanic acida 0.5 1 0.125 1 100 0 0 100 (100) 100 — 0
Ampicillin 0.5 1 0.25 128 94 1.5 4.5 NA 94.0 — 6.0
Azithromycin 0.25 1 0.06 2 100 — — 22.4 22.4 77.6 0
Cefixime 0.03 0.06 0.015 0.125 100 — — 100 100 — 0
Ceftriaxone 0.015 0.03 0.004 0.06 100 — — 100 100 0 0
Cefuroxime 1 2 0.25 4 100 0 0 73.1 0 73.1 26.9
Ciprofloxacin 0.015 0.03 0.008 0.03 100 — — 100 100 — 0
Clarithromycin 2 4 0.5 16 98.5 1.5 0 0 43.3 56.7 0
Levofloxacin 0.03 0.03 0.008 0.06 100 — — 100 100 — 0
Trimethoprim/sulfamethoxazole 0.5 16 0.06 32 59.7 7.5 32.8 59.7 59.7 — 40.3
50%, concentration required to inhibit 50% of isolates; 90%, concentration required to inhibit 90% of isolates; min, minimum MIC observed; max,
maximum MIC observed; S, susceptible; I, intermediate; R, resistant; NA, not applicable.
aAmoxicillin/clavulanic acid PK/PD susceptibility at high dose shown in parentheses.
Table 5. MIC distribution data for all H. influenzae isolates (n¼67)
Number of isolates susceptible at MIC (mg/L)
Antimicrobial 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
Amoxicillin/clavulanic acid 0 0 0 0 0 2 21 35 9 0 0 0 0 0 0 0
Ampicillin 0 0 0 0 0 0 18 28 17 1 0 0 0 0 0 3
Azithromycin 0 0 0 0 1 14 26 15 10 1 0 0 0 0 0 0
Cefixime 0 0 16 42 8 1 0 0 0 0 0 0 0 0 0 0
Ceftriaxone 6 26 21 12 2 0 0 0 0 0 0 0 0 0 0 0
Cefuroxime 0 0 0 0 0 0 1 17 31 17 1 0 0 0 0 0
Ciprofloxacin 0 11 45 11 0 0 0 0 0 0 0 0 0 0 0 0
Clarithromycin 0 0 0 0 0 0 0 12 17 24 9 4 1 0 0 0
Levofloxacin 0 4 23 39 1 0 0 0 0 0 0 0 0 0 0 0
Trimethoprim/sulfamethoxazole 0 0 0 0 11 6 9 14 1 4 10 3 5 4 0 0
SOAR: Ukraine 2011–13
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investigation. The pneumococci were universally 88.1% suscep-
tible to the macrolides azithromycin, clarithromycin and erythro-
mycin and therefore, although these agents can be given orally,
they do not provide the same level of coverage as that observed
with amoxicillin/clavulanic acid (amoxicillin) or levofloxacin. The
least active antimicrobial tested was trimethoprim/sulfameth-
oxazole, where susceptibility was ,10% (CLSI or PK/PD), but this
was 38.8% by EUCAST due to a one dilution higher breakpoint.
Therefore trimethoprim/sulfamethoxazole can be considered
inactive against pneumococci. In addition, this was the only anti-
microbial agent to have significantly different susceptibility by age
group, although the most susceptible age group (elderly) was still
only 37.5% susceptible.
H. influenzae from Ukraine were generally highly susceptible to
most antimicrobial agents, including ampicillin, due to a low
b-lactamase prevalence (6%). As with S. pneumoniae, trimetho-
prim/sulfamethoxazole activity was weak. Following CLSI recom-
mendations, susceptibility to the macrolides was 98.5%–100%.
However, analysis by PK/PD breakpoints indicates zero susceptibil-
ity to clarithromycin and only 22.4% susceptibility to azithromy-
cin. EUCAST breakpoints for azithromycin also showed 22.4%
susceptibility and a slightly higher susceptibility to clarithromycin
(43.3%). These data illustrate the continued need for the harmon-
ization of clinical breakpoints, especially in countries where clinical
laboratories may follow CLSI or EUCAST guidelines.
There are few other publications on antimicrobial resistance in
respiratory pathogens from Ukraine, but the data from this study
suggest that resistance levels are low in Ukraine compared with
other parts of Eastern Europe. For example, the penicillin non-
susceptibility rate in S. pneumoniae from Romania in 2008 was
50% and macrolide resistance was 30.9%.17 Even as far back as
2001, resistance in respiratory pathogens from Romania was
reported to be higher than that currently seen in Ukraine.18
Similarly, ampicillin non-susceptibility in respiratory isolates of
H. influenzae from Bulgaria is cited at 18%.19 Future studies are
warranted to confirm continued low resistance levels in these
respiratory pathogens from Ukraine.
The main limitations of this study stem from small sample
sizes and the attempt to draw conclusions about antimicrobial
susceptibility levels in the country using data from two hospital
sites. However, despite these limitations, patterns emerged that
can be useful for clinicians in selecting empirical therapy for
community-acquired respiratory tract infections.
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